Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:4.6.1.1 (adenylate cyclase)
 19,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The large increase in cyclic AMP accumulation by rat white fat cells seen in the presence of lipolytic agents plus methylxanthines and adenosine deaminase was markedly inhibited by lactate. However, lipolysis was unaffected by lactate. Octanoate, hexanoate, heptanoate, and beta-hydroxybutyrate inhibited both cyclic AMP accumulation and lipolysis by rat fat cells. The mechanism by which these acids inhibit lipolysis differs from that for long chain fatty acids such as oleate. Oleate directly inhibited triglyceride lipase activity of homogenized rat adipose tissue. In contrast, octanoate, beta-hydroxybutyrate, and lacatate had no effect on triglyceride lipase activity. Hormone-stimulated adenylate cyclase activity of rat fat cell ghosts was inhibited by oleate and 4mM octanoate but not by 1.6 mM octanoate, heptanoate, hexanoate, beta-hydroxybutyrate or lactate. None of the acids affected the soluble protein kinase activity of rat adipose tissue. There was no stimulation by lactate, butyrate, beta-hydroxybutyrate, or octanoate of the soluble or particulate cyclic AMP antilipolytic action of a short chain acid such as octanoate or hexanoate was not accompanied by any drop in total fat cell ATP. The mechanism by which lactate lowers cyclic AMP but not lipolysis remains to be established.
 ...
PMID:Inhibition of adenosine 3':k'-monophosphate accumulation white fat acids, lactate, and beta-hydroxybutyrate. 18 3

The unsaturated fatty acids oleic, linoleic and arachidonic inhibited binding of ligands to the ouabain, opiate, and beta-adrenergic plasma membrane receptors. Low concentrations of fatty acids slightly increased the binding of ouabain to its binding sites. The effect of these fatty acids on beta-adrenergic sensitive adenylate cyclase was more complex. 0.2-0.3 mM fatty acids increased adenylate cyclase activity, while higher concentrations of arachidonic and linoleic acids, but not oleic acid, inhibited basal, beta-agonist- and NaF-stimulated activities in membranes of A431 and C6 cells. To evaluate which aspects of the unsaturated fatty acid molecules might be responsible for the observed effects, myristic acid, monoolein and taurodeoxycholic acid were studied. They also inhibited binding to the opiate receptor. Myristic acid, did not inhibit ouabain binding, binding to beta-receptor, nor adenylate cyclase activity. Monoolein, had no inhibitory effect on ouabain binding but behaved similar to oleic acid in the beta-receptor/adenylate cyclase system. Taurodeoxycholic acid inhibited binding to all three receptors as well as adenylate cyclase activity. We conclude that the effects of unsaturated fatty acids on ligand binding and adenylate cyclase activity are the result of their multiple interactions with various molecular processes rather than any unique property of long chain unsaturated fatty acids, per se.
 ...
PMID:Multiple interactions of unsaturated fatty acids with opiate and ouabain binding sites and beta-adrenergic sensitive adenylate cyclase system. 283 16

The accumulation of long chain of acyl carnitine, which is thought to exaggerate myocardial ischemic damage, has been demonstrated in ischemic myocardium. The purpose of this study was to determine the effect of palmitoyl carnitine on the Na+, K+-ATPase and adenylate cyclase activity of myocardial sarcolemma in vitro. Controversial views exist at present regarding the effect of palmitoyl carnitine on Na+, K+-ATPase. Wood et al. [23] observed that palmitoyl carnitine inhibited the activity of Na+, K+-ATPase but this inhibition was not observed by Owens et al. [17]. We did observe an inhibition of Na+, K+-ATPase by palmitoyl carnitine. The 50% inhibition of the maximum activity was observed at a palmitoyl carnitine concentration of 110 microM and complete inhibition at 160 microM. Adenylate cyclase activity was inhibited by palmitoyl carnitine irrespective of the assay conditions. The (isoproterenol + GTP)-stimulated activity, fluoride-stimulated activity and basal activity with Mg-ATP or Mn-ATP as a substrate were all inhibited though to varying degrees. The 50% inhibition of adenylate cyclase activity was observed at 84 microM, 94 microM, 200 microM and 105 microM of palmitoyl carnitine in the above mentioned order. The inhibition curve showed a shoulder or even a peak at about 75 microM of palmitoyl carnitine. It is suggested that elevated levels of palmitoyl carnitine in ischemic myocardium may play a role in inhibiting sarcolemmal function.
 ...
PMID:Effect of palmitoyl carnitine on Na+, K+-ATPase and adenylate cyclase activity of canine myocardial sarcolemma. 632 16

We have previously described the ability of arachidonic acid (AA) to regulate GLUT4 gene expression (Tebbey, P.W., McGowan, K.M., Stephens, J.M., Buttke, T.M., and Pekala, P.H. (1994) J. Biol. Chem. 269, 639-644). Chronic exposure (48 h) of fully differentiated 3T3-L1 cells to AA resulted in an approximately 90% suppression of GLUT4 mRNA accumulation. This decrease was demonstrated to be due to a 50% decrease in GLUT4 gene transcription as well as a destabilization of the GLUT4 message (t1/2 decreased from 8.0 to 4.6 h). In the current study we have identified, at least in part, the mechanism by which AA exerts its effects on GLUT4 expression. Compatible with a cyclooxygenase mediated event, the AA-induced suppression of GLUT4 mRNA was abolished by pretreating the cells with the inhibitor, indomethacin. Consistent with this observation, exposure of the cells to 10 microM PGE2 mimicked the effect of AA, in contrast to products of the lipoxygenase pathway which were unable to suppress GLUT4 mRNA content. Quantification of the conversion of AA to PGE2 demonstrated a 50-fold increase in PGE2 released into the media within 7 h of AA addition. Cyclic AMP levels were also increased 50-fold with AA treatment consistent with PGE2 activation of adenylate cyclase. Various long chain fatty acids, including the nonmetabolizable analog of AA, eicosatetraenoic acid (ETYA), also decreased GLUT4 mRNA levels. The effect of ETYA, a potent inhibitor of both lipo- and cyclooxygenases and a potent activator of peroxisome proliferator activated receptors (PPARs), suggested the presence of a second pathway where non-metabolized fatty acid functioned to suppress GLUT4 mRNA levels. Further support for a PPAR-mediated mechanism was obtained by exposure of the cells to the classic PPAR activator, clofibrate, which resulted in a approximately 75% decrease in GLUT4 mRNA content. Nuclear extracts prepared from the adipocytes contained a protein complex that bound to the PPAR responsive element (PPRE) found in the promoter of the fatty acyl-CoA oxidase gene. When the adipocytes were treated with either AA or ETYA, binding to the PPRE was disrupted, consistent with an ability of these fatty acids to control gene expression by altering the occupation of a PPRE. However, a perfect PPRE has yet to be identified in the GLUT4 promoter, but this does not rule the possibility of a PPAR playing an indirect role in the AA-induced GLUT4 mRNA suppression.
 ...
PMID:Regulation of GLUT4 gene expression by arachidonic acid. Evidence for multiple pathways, one of which requires oxidation to prostaglandin E2. 855 42

The role played by long chain fatty acids (LCFA) in promoting energy expenditure is confounded by their dual function as substrates for oxidation and as putative classic uncouplers of mitochondrial oxidative phosphorylation. LCFA analogs of the MEDICA (MEthyl-substituted DICarboxylic Acids) series are neither esterified into lipids nor beta-oxidized and may thus simulate the uncoupling activity of natural LCFA in vivo, independently of their substrate role. Treatment of rats or cell lines with MEDICA analogs results in low conductance gating of the mitochondrial permeability transition pore (PTP), with 10-40% decrease in the inner mitochondrial membrane potential. PTP gating by MEDICA analogs is accounted for by inhibition of Raf1 expression and kinase activity, resulting in suppression of the MAPK/RSK1 and the adenylate cyclase/PKA transduction pathways. Suppression of RSK1 and PKA results in a decrease in phosphorylation of their respective downstream targets, Bad(Ser-112) and Bad(Ser-155). Decrease in Bad(Ser-112, Ser-155) phosphorylation results in increased binding of Bad to mitochondrial Bcl2 with concomitant displacement of Bax, followed by PTP gating induced by free mitochondrial Bax. Low conductance PTP gating by LCFA/MEDICA may account for their thyromimetic calorigenic activity in vivo.
 ...
PMID:Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo. 2003 59